Androgen hypersensitivity in prostate cancer: Molecular perspectives on androgen deprivation therapy strategies

Prostate

Volumn 71, Issue 5, 2011, Pages 550-557

  Foley, Ruth ^a   Marignol, Laure ^a   Keane, John P ^a,b   Lynch, Thomas H ^a,b   Hollywood, Donal ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

biomarkers; intermittent androgen withdrawal; proliferation; testosterone replacement

Indexed keywords

ANDROGEN; ANTIANDROGEN; BIOLOGICAL MARKER;

ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG WITHDRAWAL; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE; TUMOR GROWTH;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERSENSITIVITY, DELAYED; MALE; MICE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 79951529502     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21266     Document Type: Article

References (51)

1. Weckermann D, Harzmann R,. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol 2004; 46 (3): 279-283, discussion 283-274.
2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512. (Pubitemid 39315317)
3. Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K,. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy. BJU Int 2006; 97 (6): 1184-1189. (Pubitemid 43907318)
4. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur Urol 57 (1): 49-59.
5. Shore ND, Crawford ED,. Intermittent androgen deprivation therapy: Redefining the standard of care ? Rev Urol 12 (1): 1-11.
6. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI,. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56 (2): 237-244.
7. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM,. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009; 56 (1): 97-103.
8. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y, Sasano H,. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005; 12 (1): 101-107. (Pubitemid 40477091)
9. Devlin HL, Mudryj M,. Progression of prostate cancer: Multiple pathways to androgen independence. Cancer Lett 2009; 274 (2): 177-186.
10. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y,. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010; 70 (7): 745-754.
11. Umekita Y, Hiipakka RA, Kokontis JM, Liao S,. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 1996; 93 (21): 11802-11807. (Pubitemid 26347204)
12. Lee SO, Dutt SS, Nadiminty N, Pinder E, Liao H, Gao AC,. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate 2007; 67 (12): 1293-1300. (Pubitemid 47435777)
13. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ, Chung LW,. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci USA 1996; 93 (26): 15152-15157. (Pubitemid 27009568)
14. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP,. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43 (4): 1809-1818. (Pubitemid 13122588)
15. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F,. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 1991; 51 (19): 5165-5170.
16. Edwards J, Krishna NS, Grigor KM, Bartlett JM,. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89 (3): 552-556. (Pubitemid 37026442)
17. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ,. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004; 64 (24): 9209-9216. (Pubitemid 39665537)
18. Azuma K, Nakashiro K, Sasaki T, Goda H, Onodera J, Tanji N, Yokoyama M, Hamakawa H,. Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells. Biochem Biophys Res Commun 391 (1): 1075-1079.
19. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE,. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 2005; 96 (3-4): 251-258. (Pubitemid 41080506)
20. Rosenblatt AE, Burnstein KL,. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Mol Endocrinol 2009; 23 (3): 412-421.
21. Tang YQ, Han BM, Yao XQ, Hong Y, Wang Y, Zhao FJ, Yu SQ, Sun XW, Xia SJ,. Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells. Asian J Androl 2009; 11 (1): 119-126.
22. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A,. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 53 (6): 1304-1311. (Pubitemid 23097107)
23. Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC, Chang C,. Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl 2007; 9 (2): 181-188. (Pubitemid 46416578)
24. Marcelli M, Haidacher SJ, Plymate SR, Birnbaum RS,. Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 1995; 136 (3): 1040-1048.
25. Lin B, Wang J, Hong X, Yan X, Hwang D, Cho JH, Yi D, Utleg AG, Fang X, Schones DE, Zhao K, Omenn GS, Hood L,. Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS ONE 2009; 4 (8): e6589.
26. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39. (Pubitemid 38524696)
27. Horii K, Suzuki Y, Kondo Y, Akimoto M, Nishimura T, Yamabe Y, Sakaue M, Sano T, Kitagawa T, Himeno S, Imura N, Hara S,. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 2007; 5 (4): 383-391. (Pubitemid 46707000)
28. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW,. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59 (22): 5830-5835.
29. Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, Lehman T, Hollywood D, Lynch TH, Lawler M,. The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther 2009; 8 (2): 118-124.
30. Park SY, Kim YJ, Gao AC, Mohler JL, Onate SA, Hidalgo AA, Ip C, Park EM, Yoon SY, Park YM,. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006; 66 (10): 5121-5129. (Pubitemid 43844934)
31. Milosevic M, Chung P, Parker C, Bristow R, Toi A, Panzarella T, Warde P, Catton C, Menard C, Bayley A, Gospodarowicz M, Hill R,. Androgen withdrawal in patients reduces prostate cancer hypoxia: Implications for disease progression and radiation response. Cancer Res 2007; 67 (13): 6022-6025. (Pubitemid 47037480)
32. Gustavsson H, Welen K, Damber JE,. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 2005; 62 (4): 364-373. (Pubitemid 40227488)
33. Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G,. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000; 45 (1): 72-79.
34. Wade TP, Kozlowski P,. Longitudinal studies of angiogenesis in hormone-dependent Shionogi tumors. Neoplasia 2007; 9 (7): 563-568. (Pubitemid 47121830)
35. Maitland NJ, Collins AT,. Prostate cancer stem cells: A new target for therapy. J Clin Oncol 2008; 26 (17): 2862-2870.
36. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ,. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68 (13): 5469-5477.
37. Lee I, Sandler H,. Hormone therapy and radiotherapy for intermediate risk prostate cancer. Semin Radiat Oncol 2008; 18 (1): 7-14. (Pubitemid 350235951)
38. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C,. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55 (6): 1269-1277.
39. Miller K, Steiner U, Lingnau A, Keilholz U, Witzsch U, Haider A, Wachter U, Rüssel C, Altwein J,. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 2007; 25 (18S): 5015.
40. de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, Bouffioux C, Coppens L, Bonnet P, Andrianne R, Wlatregny D,. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: Results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002; 1 (3): 163-1171.
41. Theyer G, Durer A, Theyer U, Haberl I, Ulsperger E, Baumgartner G, Hamilton G,. Measurements of free and total PSA, tissue polypeptide-specific antigen (TPS), and CYFRA 21-1 in prostate cancer patients under intermittent androgen suppression therapy. Prostate 1999; 41 (2): 71-77. (Pubitemid 29446961)
42. Hara T, Nakamura K, Araki H, Kusaka M, Yamaoka M,. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Cancer Res 2003; 63 (17): 5622-5628. (Pubitemid 37139887)
43. Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O, Higano CS, Petrylak DP, Chatta GS, Arlen PM, Figg WD, Dahut WL,. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2008; 180 (4): 1432-1437, discussion 1437.
44. Eggener SE, Stern JA, Jain PM, Oram S, Ai J, Cai X, Roehl KA, Wang Z,. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Prostate 2006; 66 (5): 495-502.
45. Friedman AE,. Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009; 56 (11): 97-104. Eur Urol 2009 e36.
46. Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, Squire O, Morris M, Scher H, McCarthy T, Welch M, Larson SM, Humm JL,. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 2004; 45 (11): 1966-1971. (Pubitemid 47618458)
47. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI,. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13 (7): 2023-2029. (Pubitemid 46649868)
48. Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford ED,. Antiandrogen withdrawal in castrate-refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9426). Cancer 2008; 112 (11): 2393-2400.
49. Terada N, Shimizu Y, Yoshida T, Maeno A, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O,. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Prostate 70 (3): 252-261.
50. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M,. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63 (1): 149-153. (Pubitemid 36070433)
51. Ameri K, Luong R, Zhang H, Powell AA, Montgomery KD, Espinosa I, Bouley DM, Harris AL, Jeffrey SS,. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype. Br J Cancer 2010; 102 (3): 561-569.